TITLE

Most Doctors Back Avastin Withdrawal

PUB. DATE
February 2011
SOURCE
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p93
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the support of fifty-eight percent of physicians in a poll by Sermo, on the move of the Food and Drug Administration (FDA) to pull the breast cancer indication for Avastin from the market.
ACCESSION #
59994672

 

Related Articles

  • Avastin Gets More Time for Review.  // Pharmaceutical Representative;Oct2010, Vol. 40 Issue 10, p10 

    The article accounts on the report issued by the U.S. Food and Drug Administration regarding the extension of the review period for Avastin, a drug used to treat cancer including cancer of the breast, lungs, colon, brain, and kidneys.

  • Medicare to cover expensive cancer treatments.  // PharmacoEconomics & Outcomes News;7/16/2011, Issue 633, p11 

    The article reports on the plan of Medicare to cover Avastin bevacizumab for breast cancer treatment regardless of the decision of the U.S. Food and Drug Administration (FDA) to rescind Avastin approval for such indication in July 2011.

  • FDA warns against products with more than 325 mg acetaminophen.  // Infectious Disease News;Feb2014, Vol. 27 Issue 2, p33 

    The article reports that the U.S. Food and Drug Administration (FDA) has advised physicians to refrain from dispensing or prescribing drug products with more than 325 milligrams of acetaminophen per dosage unit because of the potential to cause severe liver damage or death as of February 2014.

  • FDA Reveals Dear Doc Letter Guidance.  // BioWorld Today;11/15/2010, Vol. 21 Issue 221, p3 

    The article reports on a new draft guidance for industry for "Dear Health Care Professional" letters issued by the U.S. Food and Drug Administration in the second week of November 2010, aimed at alerting doctors and other healthcare providers about safety concerns or other important new information.

  • Fatality Risk With Allergenic Extract Use. Nightingale, Stuart L. // JAMA: Journal of the American Medical Association;6/16/89, Vol. 261 Issue 23, p3368 

    Reports on the efforts of the U.S. Food and Drug Administration to increase physician awareness of the small but real risk of fatality with use of allergenic extracts and to encourage mortality reports by physicians. Average annual reported fatality rate following allergenic extract use; .

  • Bevacizumab in Metastatic Breast Cancer: Ready for Prime Time? Mandock, Katherine; Soefje, Scott A.; Adams, R. // Journal of Hematology Oncology Pharmacy;Dec2011, Vol. 1 Issue 4, p6 

    The article focuses on the U.S. Food and Drug Administration's (FDA) decision to remove bevacizumab's current labeled indication for metastatic breast cancer (MBC). Postapproval trials required with the FDA approval for bevacizumab for treatment did not demonstrate an overall survival (OS)...

  • Fighting Fire with Fire: Rekindling the Bevacizumab Debate. Montero, Alberto J.; Vogel, Charles // New England Journal of Medicine;1/26/2012, Vol. 366 Issue 4, p374 

    The article discusses the controversy concerning the decision of the U.S. Food and Drug Administration (FDA) to revoke bevacizumab approval in 2012. It says that the agency opposed the use of the substance when combined with paclitaxel to treat patients with metastatic breast cancer. According...

  • Advisory Panel Rejects Avastin for Breast Cancer Treatment. Koroneos, George // Pharmaceutical Executive;Aug2010, Vol. 30 Issue 8, p13 

    The article reports on the decision of the U.S. Food and Drug Administration to discontinue the use of Avastin or bevacizumab as a treatment for breast cancer due to reports on inefficacy.

  • The Pharmaceutical Medicine Year that Was. Fox, Anthony W. // Pharmaceutical Medicine - New Zealand;2008, Vol. 22 Issue 6, p341 

    The author recalls various issues related to drug safety in the U.S. which transpired in 2008. The Food and Drug Administration (FDA) has received a 9% increase in funding at $1.73 billion, 39% and 13.5% of which went to the Centers for Drug and Biologics Evaluation and Research (CDER and CBER),...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics